U.K. regulators will reportedly recommend that the National Health Service not cover Eli Lilly’s (NYSE:LLY) donanemab for the ...

Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...

UTHealth Houston is the first institution in Houston to administer an FDA-approved drug, Kisunla (donanemab-azbt), for the ...

A groundbreaking study has unveiled a potential game-changer in the fight against Alzheimer's disease. Scientists have ...

Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8.

Neurosteer's high-tech EEG brain scan enables a fast, automatic, music-driven, audio-guided test people can take during their ...

The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).